ProstaWeb: an online tool for predicting prostatic pathologies from Primary Care consultations.

Authors

  • Francisco J. Pérez-Gil Escuela Superior de Ingeniería Informática. Universidad de Castilla-La Mancha. 02071. Albacete
  • Pablo Bermejo Escuela Superior de Ingeniería Informática. Universidad de Castilla-La Mancha. 02071. Albacete
  • Alicia Vivo Centro de Salud La Roda. 022630 Albacete
  • Pedro J. Tárraga-López Centro de Salud Zona 5. 02005. Albacete

DOI:

https://doi.org/10.19230/jonnpr.1327

Keywords:

Prostate, Prostate Cancer, Telemedicine, Benign hypertrophy of the prostate, Diagnosis

Abstract

Objective: To develop a tool to support and aid the diagnosis of prostate pathologies.

Method: The database provided by a previous research project in which anthropometric, clinical and analytical variables are related to the development of predictive statistics algorithms that provide the probability of having a prostate or other pathology.

Results: A diagnostic tool that performs with some precision the probability of having a prostatic pathology or another depending on the variables that the patient includes.

Conclusions: Prostaweb is a useful and practical prostate diagnosis tool for the primary care physician. Although the hit rate is considerably high, it would still be necessary to construct models with more refined variables and perhaps with a larger number of patients, to increase the precision of the predictions. "

Downloads

Download data is not yet available.

References

Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Annals of Oncology. 2007; 18: 581-592.

Landis S, Murray T, Bolden S, Wingo P. Cancer Statistics. A Cancer Journal for Clinicians. 1999; 49: 8-31.

Brawer MK. Prostate-specific antigen: current status. A Cancer Journal for Clinicians. 1999; 49: 264-281.

Mochtar C, Kiemeney L, Laguna M, Debruyne F, de la Rosette J. PSA velocity in conservatively managed BPH: can it predict the need for BPH-related invasive therapy? The Prostate. 2006; 66: 1407-1412.

Merrick G, Butler W, Wallner K, Lief J, Hinerman-Mulroy A, Galbreath R. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy. Brachtherapy. 2003; 2:181-188.

Yuksel S, Dizman T, Yildizdan G, Sert U. Application of soft sets to diagnose the prostate cancer risk. Journal of Inequalities and Applications. 2013; 229.

Meigs J, Barry M, Oesterling J, Jacobsen S. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer. Journal of General Internal Medicine. 1996; 11: 505-512.

Bermejo P, Vivo A, Tárraga P, Rodríguez-Montes JA. Development of interpretable predictive models for BPH and prostate cancer. Clinical Medicine Insights. Oncology. 2015. 9: 15-25.

Tesis Doctoral: Diseño y evaluación de un modelo predictivo para el diagnóstico del cáncer de próstata en Atención Primaria . Vivo A. 2012. Universidad Autónoma de Madrid.

Downloads

Published

2017-01-31

Issue

Vol. 2 No. 4: (April 2017) JONNPR.2017;2(4):120-167

Section

Original

License

All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.

The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.

You are free to:

Share — copy and redistribute the material in any medium or format

Adapt — remix, transform, and build upon the material

The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

NonCommercial — You may not use the material for commercial purposes.

ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License